Mitoxantrone is a synthetic anthracenedione originally developed to improve the therapeutic
profile of the anthracyclines and is commonly applied in the treatment of breast and prostate …

Mitoxantrone, a synthetic anthracenedione, was developed in the 1980s as a doxorubicin
analogue in a program to find a cytotoxic agent with decreased cardiotoxicity compared with …

The aberrant expression of ubiquitin-specific protease 11 (USP11) is believed to be related
to tumor progression. However, few studies have reported the biological function and clinical …

The treatment landscape for relapsing forms of multiple sclerosis (RMS) has expanded
considerably over the last 10 years with the approval of multiple new disease-modifying …

Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related death
in the United States, with a 95% five-year mortality rate. For over a decade, gemcitabine …

We analyzed the effect of aspirin, salicylate, and other nonsteroidal antiinflammatory drugs
(NSAIDs) on the viability of B-chronic lymphocytic leukemia (B-CLL) cells. Aspirin induced a …

With the introduction of interferon‐β1b in 1993 as the first FDA‐approved treatment for
multiple sclerosis, the era of treatment of this incurable disease began, and its natural …

Stress granules (SGs) are assemblies of mRNA and proteins that form from mRNAs stalled
in translation initiation in response to stress. Chronic stress might even induce formation of …

Adaptation of medical treatment to a particular patient requires the monitoring the
concentration of active substances or biomarkers in the body during medical treatment …

Abstract Type 4 phosphodiesterase (PDE4) inhibitors reportedly induce apoptosis in chronic
lymphocytic leukemia (CLL) cells. Following clinical improvement of one previously …